FCGR2B and neoplasm: The increased agonism on T cell activation and anti-tumor activity was also observed in two other anti-CD40 mAbs CD40.1 (CRD2-3 binding) and CD40.2 (CRD1 binding) h1-V11 compared to their h1 or h1-SELF respectively (Dahan et al., 2016), suggesting that selective enhanced binding to FcγRIIB results in stronger agonistic activity and is rather a general rule than specific Fab clones.